12

A New Day for Medicine

Transforming Diagnostics & Drug Discovery

Diagnostics

Photo-Affinity Biomarker Purification for Accurate Diagnostics

LEARN MORE

Therapeutics

Next-Gen Proteomic Bead-Arrays for Drug and Biomarker Discovery

LEARN MORE

Making a Difference

Dr. Gargey Yagnik joins AmberGen as Program Coordinator for Mass Spectrometry. In his previous position as a postdoctoral researcher at Sanofi Genzyme he developed new methods for MALDI-MSI tissue imaging. He received his Ph.D. from Iowa State University in analytical chemistry.

AmberGen Founder and Chairman of the Board, Dr. Ken Rothschild, was elected as a Fellow of the National Academy of Inventors (NAI). The election as an NAI Fellow honors contributions from inventors who have made a tangible impact on quality of life, economic development and welfare of society.

John Gillespie, former Director of R&D for 3 Johnson & Johnson businesses including their multi-billion dollar Ethicon Products business, joins AmberGen as VP of Product and Business Development

Thermo-Fisher sells AmberGen’s PC-Biotin-NHS reagent

Pioneering New Technologies

AmberGen receives US Patent 9,910,034 increasing its broad coverage on PC-PURE™ photo-affinity biomarker purification and enrichment technology for improving the accuracy of diagnostic testing

Paper published in PLOS ONE in collaboration with Boston Children’s Hospital “Photocleavage-based affinity purification of biomarkers from serum: Application to multiplex allergy testing” describing application of AmberGen’s PC-PURE™ to highly multiplex in vitro allergy testing (AllerBead™)

AmberGen acquires a new state-of-the-art Bruker rapifleX™ MALDI mass spectrometer for ultra-fast and high resolution mass spectrometry imaging of its Bead-AMS™ proteomic bead-arrays

Paper published in Nature’s Scientific Reports “Proteome-wide drug screening using mass spectrometric imaging of bead-arrays” describing drug-discovery application of Bead-AMS™ including detection of on- and off-target drug binding

AmberGen receives US Patent 9,334,530 for its Bead-AMS™ technology describing synchronization of mass spectrometric and fluorescence images of mass-tagged bead arrays

Paper published in Liver International “Anti-Kelch-like 12 and Anti-Hexokinase 1: Novel Autoantibodies in Primary Biliary Cirrhosis” resulting from a collaboration between AmberGen, INOVA Diagnostics and MGH

AmberGen receives US Patent 8,906,700 providing broad coverage on PC-PURE™ technology for biomarker isolation and use in highly sensitive and quantitative assays

AmberGen and Massachusetts General Hospital (MGH) are awarded US Patent 8,852,956 for two new diagnostic autoantigen biomarkers for the autoimmune liver disease Primary Biliary Cirrhosis (PBC)

Paper published in Rapid Communications in Mass Spectrometry “Correlated matrix-assisted laser desorption/ionization mass spectrometry and fluorescent imaging of photocleavable peptide-coded random bead-arrays” describing proteomic applications of Bead-AMS™

Paper published in Journal of Immunological Methods “Multiplexed VeraCode bead-based serological immunoassay for colorectal cancer” detailing the development of a serological assay for colorectal cancer biomarkers based on the novel use of the VeraCode™ multiplex bead assay system

AmberGen receives US Patent 8,148,062 for detecting disease causing genetic mutations such as breast and colorectal cancer using affinity tags in translated nascent proteins

AmberGen receives US Patent 7,897,335 for electrophoresis-free methods of high sensitivity detection of chain truncation mutations using tagged translated nascent proteins

OUR NEWS

Get in Touch with us!

CONTACT US